JAQBO
Live / Registered — Registered (as of 10 Dec 2024)
What this means for you
Registered since 10 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79383436
- Registration number
- 7592609
- Mark type
- Stylized text
- Filed
- 14 Sept 2023
- Published for opposition
- 08 Oct 2024
- Registered
- 10 Dec 2024
- Attorney of record
- John M. Kim
Goods and services
- Class 005 — Pharmaceuticals: Veterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; medicines for the prevention and treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; medicines for human purposes, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; ethical medicinal preparations, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection
Owner
Prosecution history
- 06 Jun 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 15 May 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 15 May 2025 — FINAL DISPOSITION PROCESSED
- 03 May 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 15 Apr 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 15 Apr 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 10 Mar 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 08 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Oct 2024 — PUBLISHED FOR OPPOSITION
- 18 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Sept 2024 — EXAMINER'S AMENDMENT ENTERED
- 03 Sept 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED